81 results on '"Ledermann, Jonathan"'
Search Results
2. Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study
3. CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer
4. Best original research presented at the 23rd European Congress on Gynaecological Oncology—Best of ESGO 2022
5. Interviews conducted at the European Society of Gynaecological Oncology 2022 Congress: a ENYGO-IJGC Fellows initiative
6. Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study
7. Anthony Luder
8. British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic
9. Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3
10. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
11. ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
12. Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)
13. British Gynaecological Cancer Society recommendations and guidance on patient-initiated follow-up (PIFU)
14. Laparoscopic radical hysterectomy: a European Society of Gynaecological Oncology (ESGO) statement
15. Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process
16. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety
17. Perceptions, expectations, and experiences of gynecological cancer patients: a pan-European ESGO-ENGAGe survey
18. Mainstreamed genetic testing for women with ovarian cancer: first-year experience
19. Ovarian Cancer Follow-up: A Preliminary Comparison of 2 Approaches
20. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up
21. European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials Between Academic Groups and Industry Partners—First Update 2015
22. Do Cell-Cycle Phase–Specific Markers Predict Disease Grade, Stage, and Outcome in Cervical Carcinoma?
23. The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership
24. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Tumors of Low Malignant Potential (Borderline Ovarian Tumors)
25. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Mucinous Ovarian Carcinoma
26. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Small Cell Carcinoma of the Cervix
27. Editorial
28. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Ovary
29. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Squamous Cell Carcinoma of the Ovary
30. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma
31. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Sex Cord Stromal Tumors
32. ATL
33. Primary Chemotherapy for Inoperable Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without Delayed Debulking Surgery
34. Family History and Women With Ovarian Cancer
35. Benefits of Enhancing the Platinum-Free Interval in the Treatment of Relapsed Ovarian Cancer: More Than Just a Hypothesis?
36. Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer
37. 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference
38. Primary Chemotherapy: The Future for the Management of Advanced Ovarian Cancer?
39. European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Pharmaceutical Companies
40. A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population.
41. A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC).
42. An easy, fast, and accurate way for implementing the standards of care for the management of patients with endometrial carcinoma into daily clinical practice: the ESGO mobile app.
43. Best original research presented at the 23rd European Congress on Gynaecological Oncology-Best of ESGO 2022.
44. British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic.
45. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
46. ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.
47. Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process.
48. Laparoscopic radical hysterectomy: a European Society of Gynaecological Oncology (ESGO) statement.
49. Ovarian Cancer Follow-up: A Preliminary Comparison of 2 Approaches.
50. International Journal of Gynecological Cancer. Editorial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.